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Abstract 
Vascular endothelial growth factor (VEGF), an important angiogenic factor that is able to 
stimulate the proliferation and migration of endothelial cells, is the best-studied hallmark of 
angiogenesis. Neovascularization is a major cause of age-related macular degeneration (AMD) 
which is a leading cause of blindness in the elderly population. Specific molecular inhibitors of 
VEGF have been proved to be useful in the treatment of AMD. Ranibizumab and Bevacizumab 
are structurally similar to anti-VEGF drugs in the treatment of AMD. Many studies have in-
dicated that Ranibizumab and Bevacizumab are of roughly equal short-term efficacy and safety, 
Bevacizumab is an attractive alternative to Ranibizumab due to its lower cost. However, only 
Ranibizumab has received Food and Drug Administration (FDA) approval for the treatment of 
macular degeneration. More multicenter clinical trials are required to compare the relative 
efficacy and safety of these two drugs and some progress has been achieved. This review 
discusses the clinical effectiveness, safety, cost and other practical implications of Ranibizumab 
and Bevacizumab. 
Key words: Ranibizumab; Bevacizumab; vascular endothelial growth factor (VEGF); age-related 
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1. Introduction 
Vascular endothelial growth factor (VEGF) and 
its receptor (Flt/VEGFR family) system play a critical 
role not only in physiological but also in most parts of 
pathological angiogenesis including age-related mac-
ular  degeneration  (AMD).  In  recent  years,  several 
laboratories  have  dedicated  to  research  on  the  im-
portant  members  involved  in  angiogenesis,  particu-
larly on VEGF-VEGFRs. VEGF binding to VEGF re-
ceptor-2 (VEGFR-2) starts a tyrosine kinase signaling 
cascade  in  endothelial  cells  that  stimulates  the  pro-
duction of factors to be associated with vascular per-
meability  (eNOS)  [1],  proliferation/survival  (bFGF) 
[2],  migration  (ICAMs/VCAMs/MMPs)  [3]  and  fi-
nally  differentiation  into  mature  blood  vessels  as 
shown in Figure 1.  
Angiogenesis refers to the physiological process 
of the growth of new blood vessels. It is a normal and 
vital process for growth, development, wound heal-
ing and reproduction [4]. Angiogenesis is a complex 
process involving angiogenic factors, endothelial cells 
and  extracellular  matrix  (ECM)  components.  The 
process undergoes three well-characterized phases of 
development.  First,  angiogenic  growth  factors  acti-
vate receptors that are expressed on the endothelial 
cells  following  the  biological  signal  stimulation.  Se-
cond,  the  activated  endothelial  cells  start  to  release 
Ivyspring  
International Publisher   Theranostics 2011, 1 
 
http://www.thno.org 
396 
enzymes  known  as  proteases  which  degrade  the 
basement  membrane  to  allow  endothelial  cells  to 
spread from the primary vessel walls. Third, the pro-
liferative  endothelial  cells  together  with  the  sur-
rounding  matrix  form  solid  sprouts  connecting 
neighboring vessels.  
When the precise balance between growth and 
inhibitory  factors  of  angiogenesis  is  disturbed,  the 
excessive  or  insufficient  angiogenesis  results  in  the 
growth of abnormal blood vessels which is dramati-
cally  involved  in  the  development  of  age-related 
blindness,  cancer,  skin  diseases,  stroke,  diabetic  ul-
cers, cardiovascular disease and many other diseases. 
Angiogenesis is a major contributor to AMD, the 
fastest growing form of macular degeneration. There 
are 20 million new cases of AMD in the United States 
and millions more worldwide each year. Two types of 
AMD,  "wet"  or  neovascular  and  "dry"  or  atrophic 
have been well studied. Nowadays, most treatments 
are available for the "wet" AMD. Several anti-VEGF 
drugs have been developed, after vascular endothelial 
growth factor A (VEGFA) was found to be a key agent 
in neovascularization and vascular leakage in AMD 
[5]. 
Currently,  Ranibizumab (Lucentis) and Bevaci-
zumab (Avastin) are two major anti-VEGF drugs for 
the treatment of AMD. Ranibizumab was licensed by 
FDA  in  June  2006,  while  Bevacizumab  with  similar 
molecular  structure  to  Ranibizumab  has  also  been 
proved  to  be  highly  effective  for  AMD.  More  im-
portantly, the latter is much cheaper, and therefore is 
economically  meaningful  for  lower-income  popula-
tions.  However,  up  to  now  only  Bevacizumab  has 
been approved by FDA for the treatment of some ma-
lignancies such as colon cancer, but not for the treat-
ment  of  macular  degeneration.  As  an  alternative, 
many  ophthalmologists  are  using  Bevacizumab 
"off-label" to treat AMD. Controversies remain over 
whether Ranibizumab or Bevacizumab is superior in 
treating macular degeneration. Therefore, this review, 
based on our knowledge of VEGF and its receptors as 
well  as  the  AMD,  tries  to  compare  the  clinical  ad-
vantages and disadvantages of these two drugs. 
 
2. VEGF and VEGF receptors 
VEGF  family  includes  VEGF-A,  VEGF-B, 
VEGF-C,  VEGF-D,  VEGF-E  and  placental  growth 
factor  (PlGF),  among  which  the  most  important 
member is VEGF-A [6]. The VEGF family has distinct 
binding affinities for VEGFR-1, -2, and -3. Members of 
VEGF  family  contain  a  common  structure  of  eight 
characteristically spaced cysteine residues in a VEGF 
homology domain. VEGF-A was first identified in the 
media conditioned by bovine pituitary follicular cells 
[7].  It  is  a  34-  to  42-kDa,  dimeric,  disulfide-bound 
glycoprotein that is specifically activated on endothe-
lial cells and plays a key role in various processes such 
as inducing angiogenesis, accelerating the endothelial 
cell growth, promoting cell migration, and inhibiting 
apoptosis and tumor growth. 
 
Figure 1. Schematic of vascular endothelial growth factor (VEGF) pathway. VEGFR2 is the main signal transducing VEGF 
receptor for angiogenesis and mitogenesis of endothelial cells. In endothelial cells, the VEGF signal system can adjust the 
vascular permeability through eNOS. However, the developing vasculature also requires other signaling pathways, including 
the FGF and the ICAMs/VCAMs/MMPs, and so on. Theranostics 2011, 1 
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 At  least  six  VEGF-A  isoforms  including 
VEGF121,  VEGF145,  VEGF165,  VEGF183,  VEGF189,  and 
VEGF206  are  produced  by  alternative  eight  exon 
splicing  of  the  VEGFA  gene  [8].  Among  these 
isoforms,  VEGF121  and  VEGF165  are  predominantly 
expressed in the eye [9]. At least two different mech-
anisms may control the availability of VEGF-A pro-
teins in endothelial cells: one as freely diffusible pro-
teins, such as VEGF121 and VEGF165; another one as its 
longer isoforms, such as VEGF189 and VEGF206, which 
release into a soluble and bioactive form locally from 
their bound state by protease cleavage or other means 
[10].  
There  are  three  receptor  tyrosine  kinases  that 
mediate  the  angiogenic  functions  of  VEGF  family 
members: VEGFR-1/Flt-1, VEGFR-2/KDR/Flk-1, and 
VEGFR3/Flt-4. All of them have an extracellular por-
tion  including  7  immunoglobulin-like  domains,  a 
single  transmembrane  spanning  region,  and  an  in-
tracellular portion containing a split  tyrosine-kinase 
domain  [11].  VEGFR-1  and  VEGFR-2  are  expressed 
predominantly in vascular endothelial cells and exert 
important  effects  on  the  physiological  functions. 
VEGFR-3  is  mainly  found  in  venous  endothelium 
during  early  embryonic  development  and  then  be-
comes  restricted  in  lymphatic  endothelial  cells  and 
certain fenestrated blood vascular endothelial cells in 
the adults [12]. 
Several  lines  of  evidence  have  revealed  that 
VEGF has potent pro-angiogenic effects in the retina 
and choroids; for example, the significantly increased 
VEGF  immunoreactivity  is  associated  with  the  dia-
betic retina and choroid [13] and VEGF levels are el-
evated in the vitreous of patients with subretinal ne-
ovascularization [14], which suggests that VEGF may 
contribute to the increased vascular permeability and 
angiogenesis. VEGF overexpression may promote the 
pathological neovascularization by directly stimulat-
ing angiogenesis, sustaining endothelial cell survival 
via inhibiting apoptosis, and/or enhancing vascular 
permeability by the formation of endothelial fenestra-
tions that predispose to haemorrhage and exudation. 
Moreover,  it  up-regulates  the  expression  of  matrix 
metalloproteinases, enzymes that break down extra-
cellular matrix and thus facilitate the invasion of new 
vessels into the tissues [15]. 
3. Age-related macular degeneration (AMD)  
AMD is a common disease that usually affects 
the older adults (>50 years) and results in a loss of 
vision in the center of the visual field (the macula). 
Although  children  and  adolescences  can  also  suffer 
from an inherited form of macular degeneration often 
known as "macular dystrophy", this condition is rare.  
The retina normally locates in the inner layer of 
the eye and contains optic nerves. At the back of the 
retina lies the choroid, which contains the blood sup-
ply to all three layers of the eye, including the macula, 
an  oval-shaped  highly  pigmented  yellow  spot  near 
the center of the retina; it surrounds the optic disc. At 
the early stage of AMD, most people have good vi-
sion. As the disease develops into the advanced stage, 
80-90% of patients will develop dry or nonexudative 
AMD,  during  which  waste  cellular  debris  (or 
“drusen”)  accumulates  between  the  retina  and  the 
choroid, and the retina can become detached. When 
the drusen gets bigger and denser and the pigmented 
cell  layer  under  the  macula  becomes  disturbed,  the 
vision begins to degrade.  
On the contrary, wet or neovascular, exudative 
AMD, resulting from abnormal blood vessel growth 
(choroidal  neovascularization,  CNV)  in  the  chori-
ocapillaris, is more severe, and approximately 90% of 
vision loss is due to this type. Patients with wet AMD 
can suffer from retinal detachment. The new abnor-
mal  vessels  are  fragile, and  often  extravasate  blood 
components, which occasionally lead to subretinal or 
vitreous  haemorrhage,  resulting  in  sudden  visual 
disturbance. Although the exact mechanisms for the 
development of CNV are  poorly understood, tissue 
hypoxia  and  VEGF  overexpression  may  play  im-
portant  roles.  For  example,  hypoxia-inducible  fac-
tor-1(HIF-1) plays a crucial role in the activation of 
VEGF genes involved in the angiogenesis processes of 
CNV [16]. Elevated VEGF levels have been found in 
laser-induced CNV animal models [17] and in surgi-
cally  excised  CNV  membranes  [18],  AMD  patients 
with  active  CNV  have  significantly  higher  plasma 
VEGF levels than normal controls [19]. 
The neovascular AMD can be treated with laser 
coagulation, or with angiogenesis inhibitor that stops 
and sometimes reverses the growth of blood vessels. 
Unfortunately,  no  highly  effective  treatment  is  cur-
rently available for wet AMD. However, new drugs 
known as anti-angiogenic or anti-VEGF agents have 
been found to be able to reverse the growth of ab-
normal blood vessels and improve vision after having 
been injected directly into the vitreous humor of the 
eye without bringing damage to the retina. Although 
the  current  therapies  still  cannot  cure  AMD,  an  in-
creasing number of anti-VEGF agents are under in-
vestigation. 
4. Ranibizumab (Lucentis) 
A clinical trial study on VEGF inhibition in ocu-
lar neovascularization in late 2004 initiated a new era 
of  AMD  treatment,  this  trial  demonstrated  that Theranostics 2011, 1 
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VEGF-targeted treatment could affect the formation of 
neovascular  vessels  in  patients  with  AMD.  The  re-
search  team  firstly  confirmed  that  pegaptanib 
(Macugen)  appeared  to  be  an  effective  therapy  for 
neovascular  AMD  [20].  Ranibizumab  also  is  a 
VEGF-targeted agent. Today, it has been widely used 
as  the  first-line  treatment  for  neovascular  AMD. 
Ranibizumab  is  a  recombinantly  produced,  human-
ized monoclonal antibody  fragment (Fab) designed to 
bind  and  inhibit  all  biologically  active  isoforms  of 
human VEGF, in contrast to pegaptanib that binds to 
a single isoform [21]. It has only one antigen-binding 
domain and is administered via intravitreal injection 
[22]. Since the mature product is a small molecule and 
can deeply penetrate into the tissues, it is especially 
effective for CNV beneath retinal pigment epithelial 
cells.  
More  recently,  the  Minimally  Classic/Occult 
Trial of the Anti-VEGF Antibody to Ranibizumab in 
the treatment of neovascular age-related macular de-
generation  (MARINA)  (in  which  716  patients  were 
randomly treated with intravitreal injections of 0.3 or 
0.5  mg  Ranibizumab  or  sham  injections)  demon-
strated  that  intravitreal  administration  of  Ranibi-
zumab for 24 months prevented vision loss and im-
proved  mean  visual  acuity.  More  specifically,  the 
mean increases in visual acuity were 6.5 letters in the 
0.3-mg group and 7.2 letters in the 0.5-mg group, as 
compared  with  a  decrease  of  10.4  letters  in  the 
sham-injection group. In addition, the rates of severe 
adverse events were lower in patients with minimally 
classic  or  occult  (without  classic  lesions)  choroidal 
neovascularization secondary to AMD. The benefit in 
visual acuity was maintained for 2 years [23]. Thanks 
to the amazing results of this trial, Ranibizumab was 
licensed by the US FDA in 2006 for the treatment of 
advanced or wet AMD. In another study on the role of 
Ranibizumab  for  neovascular  AMD,  the  anti-VEGF 
antibody  for  treatment  of  predominant  classic  cho-
roidal neovascularization in age-related macular de-
generation  (ANCHOR)  group  also  found  that 
Ranibizumab improved visual acuity at one year on 
average,  with  low  rates  of  severe  ocular  adverse 
events. In the ANCHOR study, the mean visual acuity 
increased by 8.5 letters in the 0.3-mg group and 11.3 
letters in the 0.5-mg group, as compared with a de-
crease of 9.5 letters in the control group [24]. 
The most common adverse effects of intravitreal 
Ranibizumab include conjunctival haemorrhage, eye 
pain and vitreous floaters. In the MARINA study, the 
incidences of endophthalmitis and severe uveitis after 
intravitreal administration of Ranibizumab were 1.0% 
(5  of 477  patients)  and  1.3%  (6  of  477  patients),  re-
spectively. However, the incidences of systemic com-
plications  such  as  hypertension  and  arterial  throm-
bolic events showed no significant difference between 
the Ranibizumab group and control group [23]. In the 
ANCHOR  study,  the  incidences  of  endophthalmitis 
and severe uveitis were 0.7% (2 of 277 patients) and 
0.4%  respectively  in  the  Ranibizumab  group,  with 
increased  immunoreactivity  to  Ranibizumab  in 
0.5-mg Ranibizumab group. Transient change in the 
intraocular  pressure  after  injection  was  common  in 
the Ranibizumab group. Again, there was no signifi-
cant  difference  in  the  rates  of  arterial  thrombolic 
events  between  the  treatment  groups  [24].  Macha-
linska  et  al  also  indicated  that  intravitreal  Ranibi-
zumab did not induce significant systemic effects or 
vascular impairment [25]. 
5. Bevacizumab as good as Ranibizumab 
   Like  Ranibizumab,  Bevacizumab  is  another 
monoclonal  antibody  that  binds  and  inhibits  all 
isoforms of VEGF with a lower affinity. As a larger 
molecule,  Bevacizumab  has  a  longer  half-life  about 
17-21 days [26] and has two antigen-binding domains. 
Intravenous Bevacizumab was approved by the FDA 
for  the  treatment  of  metastatic  colorectal  cancer  in 
February  2004.  At  that  time,  Bevacizumab  was  not 
regarded as a useful agent for the treatment of AMD 
because this full-length antibody was not believed to 
be able to penetrate the retina [27], according to the 
observation that molecules larger than 77 kDa could 
not  freely  diffuse  across  fixed  human  retina  [28]. 
However, in 2005, Rosenfeld et al. reported that visual 
acuity and macular appearance were improved under 
optical coherence tomography (OCT) after single eye 
treatment  of  neovascular  AMD  with  intravitreal 
Bevacizumab. Since then, off-label use of intravitreal 
Bevacizumab has become an alternative for patients 
who were not suitable for or refractory to other ap-
proved  therapies.  Meanwhile,  animal  studies  also 
have  found  that  this  particular  full-length  antibody 
could penetrate all retinal layers [26]. 
Several  clinical  trials  have  demonstrated  that 
Bevacizumab was beneficial for the treatment of AMD 
without severe adverse effects [26, 29, 30]. Although 
no formal dose-ranging or dose-frequency study has 
been performed, the most commonly used dose in the 
published literatures is 1.25 mg [31]. In the past, safety 
was a major concern on the off-label use of Bevaci-
zumab for macular degeneration, especially when US 
FDA warned in January 2005 that Bevacizumab, when 
used  to  treat  colon  cancer  and  other  malignancies, 
significantly increased the risk of stroke, heart attack, 
and other related adverse events [32, 33]. However, 
according to the results of the International Intravi-
treal Bevacizumab Safety Survey, although there were Theranostics 2011, 1 
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some procedure-related adverse events and systemic 
adverse  events  after  the  intravitreal  injection  of 
Bevacizumab,  these  adverse  events  occurred  in  less 
than 0.21% of the patients after 7,113 injections in total 
[34]. Furthermore, Shima et al. reported that the inci-
dence of complications (total 707 patients) within two 
months after intravitreal injection was less than 0.42% 
[35].  Therefore,  it  is  easy  to  conclude  that  the 
short-term safety of intravitreal Bevacizumab is sat-
isfactory, although the long-term safety remains un-
known.  
6. The difference between Ranibizumab and 
Bevacizumab  
Anti-VEGF therapies have been widely accepted 
to  treat  AMD.  The  epitope  of  Ranibizumab  and 
Bevacizumab locate in the receptor-binding region of 
VEGF, both antibodies target VEGF in a similar way. 
What is the difference? First, Bevacizumab (149 kDa) 
and Ranibizumab (48.39 kDa) have different molecu-
lar  weights,  mainly  because  Ranibizumab  does  not 
contain an Fc part; second, Bevacizumab is produced 
in  a  eukaryotic  cell  line  (CHO  cells)  and  is 
N-glycosylated in its Fc region, while Ranibizumab is 
produced in prokaryotic E. coli, and therefore it does 
not  carry  any  glycosylation  sites  [36].  Both  Bevaci-
zumab and Ranibizumab neutralize VEGF and appear 
to have lasting effects even after they disappear in the 
culture medium [37]. 
Controversies  remain  in  the  past  years  over 
whether Ranibizumab or Bevacizumab is superior in 
treating macular degeneration. Several recent animal 
experiments did not offer enough evidences for  de-
tecting the important differences in the efficacy and 
safety of intravitreal Bevacizumab and Ranibizumab 
in the treatment of neovascular age-related macular 
degeneration (nAMD) [38, 39]. Fong et al. concluded 
that  both  Ranibizumab  and  Bevacizumab  groups 
showed similar improvement and stability of vision 
over  time  [40].  Serum  concentrations  of  both  drugs 
following intravitreal administration were extremely 
low  [41,  42].  However,  Ranibizumab  shows  greater 
efficiency when it is highly diluted. 
In terms of ocular and systemic safety, endoph-
thalmitis,  conjunctival  haemorrhage,  and  thrombo-
embolic  events  such  as  angina,  heart  attacks  and 
strokes remain the most common problems. Rich ex-
periences  in  the  usage  of  both  Ranibizumab  and 
Bevacizumab have well demonstrated that the severe 
adverse  events  showed  no  significant  differences 
between the intravitreal Ranibizumab and intravitreal 
Bevacizumab  groups  [43,  44].  Choi  et al.  found  the 
sustained elevated intraocular pressures after intravi-
treal  injection  of  Bevacizumab,  Ranibizumab,  and 
pegaptanib.  The  elevated  intraocular  pressure  also 
showed no association with the type, frequency, and 
dose of the anti-VEGF agents [45]. 
Since  it  has  been  widely  recognized  that 
Bevacizumab is equally effective and safe as Ranibi-
zumab, it is controversial for the curative effects and 
safeties to switch one treatment for another when it 
does not work well. Patients with CNV who devel-
oped tachyphylaxis after the use of Ranibizumab or 
Bevacizumab may respond well to another anti-VEGF 
drug.  In  a  clinical  study,  81%  cases  demonstrated 
some responses after switching therapies [46]. How-
ever, Karagiannis et al. indicated that the change of 
treatment from Bevacizumab to a less than half-sized 
molecule (e.g. Ranibizumab) with less half-life in the 
vitreous contributed to a transient "instability" in the 
eye  that  might  have  triggered  the  large  subretinal 
hemorrhage [47]. 
Furthermore,  it  is  still  a  question  whether 
Bevacizumab  really  shares  identical  efficacy  and 
safety with Ranibizumab, at least for some authors. 
They argue that anibizumab, as a US FDA-approved 
agent for AMD, has been well studied in many ran-
domized clinical trials with more long-term findings 
when  compared  with  Bevacizumab.  Ranibizumab 
represents greater activity in vitro; as a smaller mole-
cule, it is easier to penetrate the eye's retina and in-
hibit abnormal blood vessel growth. Therefore, they 
believe Ranibizumab is more effective and safer than 
Bevacizumab.  For  example,  in  Chang  et  al.’s  retro-
spective  comparative  study,  the  authors  concluded 
that  the  short-term  effectiveness  of  Ranibizumab 
treatment, as measured by incremental improvement 
in  OCT  parameters,  was  significantly  better  than 
Bevacizumab treatment [48]. 
Similarly, a Japanese randomized trial reported 
that 5 patients (14.3%) developed severe intraocular 
inflammation  after  an  intravitreal  injection  of  the 
same dose of Bevacizumab [49]. Hoffmann−La Roche 
reported  32  cases  of  endophthalmitis  after  the 
off-label intravitreal use of Bevacizumab in Canada. 
Recently,  acute  postoperative  endophthalmitis  de-
veloped in 55 of 116 patients after intravitreal injection 
of  Bevacizumab  in  Shanghai,  China  [50].  Therefore, 
the safety of Bevacizumab should be further studied. 
Furthermore,  many  clinicians  have  an  impres-
sion that Bevacizumab seems to be longer-acting than 
Ranibizumab, perhaps because Bevacizumab impedes 
clearance from the eye based on its larger size. It has 
been concluded that the degeneration of photorecep-
tors cells, primarily in the macula, may account for the 
loss of central vision of patients suffering from a va-
riety of eye diseases including macular degeneration, 
especially when Bevacizumab treatment is performed Theranostics 2011, 1 
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at  higher  doses  and/or  for  a  longer  period  of  time 
[51].  Consequently,  instead  of  using  the  existing 
treatment schemes, many clinicians prefer to choose a 
regimen using less frequent dosing of Bevacizumab 
than Ranibizumab.  
Does this mean that Ranibizumab is better than 
Bevacizumab in treating AMD? Not necessarily. It has 
been indicated that Bevacizumab accumulated within 
retinal  pigment  epithelial  (RPE)  cells,  possibly  in-
ducing  long-term  effects;  on  the  contrary,  Ranibi-
zumab did not accumulate [52]. Therefore, there may 
be substantial differences in the pharmacokinetics of 
these two macular degeneration drugs.  
Moreover,  Ranibizumab  is  expensive  which 
costs  to  exceed  $9  billion  per  year  in  U.S.  and  one 
Ranibizumab injection is expected to cost $1950. For-
tunately,  the  cost  for  each  Bevacizumab  injection  is 
only about $50. The cost-effectiveness should always 
be considered when making clinical decisions. Con-
sidering its low cost and comparable efficacy/safety, 
many doctors and patients would agree that Bevaci-
zumab  is  a  better  choice  in  treating  AMD.  Table  1 
summarizes  the  sameness  and  difference  between 
Ranibizumab and Bevacizumab. Actually, more mul-
ticenter clinical trials are comparing the effectiveness 
and safety of these two drugs. 
7. Possible choices for other diseases besides 
AMD 
Besides  AMD,  VEGF  is  also  a  main  factor  of 
other eye diseases including diabetic macular edema 
(DME), central retinal vein occlusion (CRVO), retinal 
vascular thrombosis and CNV caused by other dis-
orders  such  as  high  myopia.  Since  VEGF-targeted 
drugs work well for wet AMD, they may also be ef-
fective and safe for these diseases mentioned above. 
For example, intraocular injections of 0.5-mg Ranibi-
zumab  significantly  reduced  foveal  thickness  and 
improved visual acuity in patients with chronic DME 
[53].  However,  a  randomized,  controlled  and  dou-
ble-masked trial is urgently needed to clarify whether 
intraocular  injection  of  Ranibizumab  provides 
long-term  benefit  to  patients  with  DME.  Actually, 
Ferrara  et al. had  evaluated  the  effectiveness  of  in-
travitreal Bevacizumab for CRVO. In their study, pa-
tients with CRVO of fewer than three-month duration 
received  intravitreal  Bevacizumab  as  the  primary 
treatment.  The  patients  experienced  a  dramatic  im-
provement  in  the  visual  acuity  and  clinical  fundus 
appearance  without  collateral  vessel  formation  [54]. 
This finding also implies that early initiation of an-
ti–VEGF  treatment  should  be  further  studied  in  a 
larger trial for CRVO. 
8. Conclusions 
The  past  decade  has  witnessed  the  promising 
potential effect of Ranibizumab and Bevacizumab in 
treating AMD due to their potent anti-VEGF proper-
ties.  With  similar  structure,  Ranibizumab  and 
Bevacizumab have their certain dose regimen, effec-
tiveness and safety. However, it still remains contro-
versial whether Ranibizumab or Bevacizumab has the 
better  cost-effectiveness  for  AMD  treatment.  More 
rigorously designed multicenter clinical trials are ur-
gently needed to evaluate the long-term effectiveness 
and safety of these two drugs. 
 
Table 1. The sameness and difference between Ranibizumab and Bevacizumab. 
  Ranibizumab  Bevacizumab 
The sameness      
Target  VEGF  VEGF 
Product  Monoclonal antibody  Monoclonal antibody 
Epitope  Receptor-binding region  Receptor-binding region 
The difference     
Molecular weight  48.39 kDa  149 kDa 
Half-life  3 days  17-21 days 
Glycosylate   No  Yes 
Expression system  E. coli  CHO cells 
Effectiveness   Strong  Strong 
Safety  Uncertain  Uncertain 
Cost  $1950 per dose  $50 per dose 
FDA-approved  For AMD  For cancer 
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